Regeneron Pharmaceuticals Inc (REGN.OQ)
271.12USD
10:54am EDT
$1.06 (+0.39%)
$270.06
$272.57
$274.19
$267.81
37,776
226,595
$283.00
$131.50
About
Overall
| Beta: | 0.96 |
| Market Cap (Mil.): | $26,456.74 |
| Shares Outstanding (Mil.): | 97.97 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| REGN.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 36.51 | 47.13 | 37.76 |
| EPS (TTM): | 7.40 | -- | -- |
| ROI: | 51.25 | -2.58 | 18.76 |
| ROE: | 87.68 | -2.66 | 19.59 |
UK cost agency recommends Bayer, Regeneron eye drug
LONDON, May 31 - Britain's healthcare cost watchdog NICE is recommending a new eye drug from Bayer and Regeneron, after a price discount was offered for its use on the state health service.
Regeneron settles all pending litigation with Roche's Genentech
May 20 - Regeneron Pharmaceuticals Inc said it settled all pending litigation with Roche Holding AG's unit Genentech on the company's eye drug, Eylea, and cancer drug, Zaltrap.
FEATURE-Fast climbing biotech Regeneron still has room to grow
* Shares jump five-fold in two years, market value $26 bln
UPDATE 2-Regeneron raises Eylea sales view, shares hit all-time high
* Shares hit life-high of $270 (Adds comments from conference call, analyst comment)
Regeneron raises 2013 Eylea sales view, profit beats Street
- Regeneron Pharmaceuticals Inc's first-quarter results beat analysts' estimates for the seventh straight quarter as sales of its eye drug Eylea continued to gather pace, and the company raised its 2013 sales estimate for the drug.
Regeneron raises 2013 Eylea sales view, profit beats Street
May 3 - Regeneron Pharmaceuticals Inc's first-quarter results beat analysts' estimates for the seventh straight quarter as the sales of its eye drug Eylea continued to gather pace, and the company raised its 2013 sales estimate for the drug.
UPDATE 3-Allergan delays drug that would rival Regeneron's Eylea
May 1 - Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands to gain from a lack of new competition.
BRIEF-Regeneron Pharma shares resume trading, up 16 percent
NEW YORK, May 1 - Regeneron Pharmaceuticals Inc : * Shares resume trading, up 16 percent * Shares as shares of Allergan slide after co says vision drug approval
BRIEF-Regeneron Pharma shares halted, last up 14.3 pct
NEW YORK, May 1 - Regeneron Pharmaceuticals Inc : * Shares halted, last up 14.3 percent
BRIEF-Regeneron Pharma shares up 2.8 pct after the bell
NEW YORK, April 24 - Regeneron Pharmaceuticals Inc : * Shares up 2.8 percent after the bell, to join S&P 500 next week
Competitors
| Price | Change | |
|---|---|---|
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Pfizer Inc. (PFE.N) | $29.18 | -0.05 |
| Bayer AG (BAYGn.DE) | €89.07 | +1.72 |
| Bayer AG (BAYE.F) | -- | -- |
| Onyx Pharmaceuticals, Inc. (ONXX.OQ) | $133.50 | +2.20 |
| Abbott Laboratories (ABT.N) | $36.92 | +0.29 |
| Sanofi SA (SASY.PA) | €76.35 | -3.82 |
| Merck & Co., Inc. (MRK.N) | $48.13 | -0.04 |
| Amgen, Inc. (AMGN.OQ) | $109.04 | +0.75 |
| Roche Holding Ltd. (ROG.VX) | CHF228.00 | -3.50 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

